Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05845996 · ClinicalTrials.gov registry record · Phase 1
Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05845996 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 56 participants.
The verdict
NCT05845996, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
Primary Objective is the tolerability and safety of ascending single and repeated intravenous infusion (IV) and/or subcutaneous (SC) administration of SAR441344
Interventions
- DRUG placebo
- DRUG SAR441344
- BIOLOGICAL Keyhole limpet hemocyanin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2018-11-08 |
| Est. Completion | 2020-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05845996
The ClinicalTrials.gov registry entry for NCT05845996 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT05845996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05845996 about?
NCT05845996 is a clinical study titled "Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects". Primary Objective is the tolerability and safety of ascending single and repeated intravenous infusion (IV) and/or subcutaneous (SC) administration of SAR441344
What is the current status of trial NCT05845996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2018-11-08. Estimated completion is 2020-04-10.
What interventions are being tested in trial NCT05845996?
The interventions under investigation include: placebo (DRUG), SAR441344 (DRUG), Keyhole limpet hemocyanin (BIOLOGICAL).
Who is sponsoring clinical trial NCT05845996?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.